Hot Investor Mandate: Corporate VC Invests in Early-Stage Life Science Companies, With Strongest Interests in Therapeutics Across All Modalities

20 Apr

A corporate venture arm of a global company has offices in US and Europe. This fund makes equity investments in early stage companies several industries, including healthcare and life sciences. The firm typically leads or co-leads rounds as a member of a syndicate of investors, and is actively seeking new investment opportunities across all funds.

Within life sciences, the firm is looking for early stage companies working primarily within therapeutics, but is open to other sectors and has made investments in medical devices, diagnostics, and digital health. The firm seeks to invest in areas of strategic interest to its parent company including Immunology (Autoimmune), Oncology, Immuno-oncology, and Fertility. The firm generally looks for companies with novel first-in-class preclinical stage assets as well as novel platform technologies. In addition, the firm is seeking innovation for process, research and/or applied solutions.

The firm is looking for privately held companies with experienced management teams able to take innovative solutions into commercially viable products. The firm looks to take an active role following investing taking a board seat. The firm is able to invest globally.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based Family Office Invests Globally, With Broad Interests in Promising Life Science Technologies

20 Apr

A family office based in the US represents approximately 2100 doctors, HNW investors, and angel investors. The firm invests in, but is not limited to, biotechnology, medical devices, and pharmaceuticals. Typical allocation size is $100k-250k per investor, participating in both leading investments and co-investing. The firm invests in companies worldwide, with no specific geographic preferences. Recently, the firm had 3 exits in the life science sector.

The firm is opportunistic in terms of sectors of interest. The firm invests in biotechnology, medical devices, pharmaceuticals, and anything relevant to life sciences that seems to be a good opportunity for the firm. The firm is open to all financial rounds and all stages of development as well as orphan diseases and all indications.

The firm does not have any management team requirements, although depending on the case, taking a board seat may be requested.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: China-Based Company Seeks Global Investment and Strategic Partnering Opportunities With Innovative IVD Products

20 Apr

A large high-tech biological company focuses on rapid diagnostics in China – the company has gone public a few years ago. Apart from their headquarters, the firm has an international presence in Europe, Asia, and North America. The firm is open to different forms of partnership including license-in, joint venture, buyout, and equity investment for early-stage companies.

The firm has a strong interest in IVD sectors for innovative products addressing the unmet needs of healthcare providers.

The firm is open to global opportunities while preferring companies with a Chinese angle.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Global Roadshow Information and Preparation

13 Apr

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

Life Science Nation (LSN)’s Redefining Early Stage Investment (RESI) conference stands out from the average partnering conference. LSN, from the start, wanted RESI to be a dedicated partnering-centric event.  RESI content is centered on startups and the information they need to succeed in their fundraising endeavors, comprising of investor and licensing partner panels and service provider workshops (see program guides below). There are two main parts to the equation, the 10,000+ early-stage capital investors and licensing partners in the LSN ecosystem, and the 10,000+ startups that are a fit for RESI. This includes those seeking up to 2M in seed funding, $2-10M series A funding, and $10M to 50M series B funding.

The LSN BD staff are not just selling RESI tickets or the LSN investor database but spend a lot of time assessing and making sure that RESI attendees are ready for a global fundraise and understand what it takes to go from the regional stage to the global arena. LSN really cares about the ROI for our clients. It is because of this challenge I have put a bunch of useful links and info that we send along to our RESI and Data leads so that they know what to expect when designing and launching a global roadshow.

At first glance, there are a lot of links/info, but we have found that startups who really want to understand what LSN and RESI are all about typically take the time to explore the subtlety and nuances of going from a regional to a global roadshow mindset.

  • Big4Bio Interview

Listen to the podcast from LSN’s CEO, Dennis Ford, about the journey and challenges life sciences entrepreneurs make when they set out to raise money, what investors care about, and what steps they can take to ensure their success best.

The most successful entrepreneurs are always the best storytellers. Finding a way to formulate your company’s unique story naturally and portraying this through multiple modalities, whether it be a 1-minute elevator pitch or a 12-slide pitch deck, is one of the most effective ways to get potential investors and partners on board with your value proposition. This video will cover the importance of entrepreneurial agency, finding your voice and developing a compelling narrative for the players that will emerge along a deal chain, and language tools to refine your hook.

Launching a startup begins with commitment. Commitment to your startup initiative, your executive team, and your partners. Learn how to sustain this commitment by creating a proof of concept or prototype and create market traction initially, considerations to your corporate structure, simplifying finances in the beginning, and what tools to utilize. This video takes you through an honest look at best practices for launching a life science startup.

  • RESI Program Guide

Life Science Nation (LSN) has developed a curriculum on the fundamentals of launching a global partnering campaign. 3 different options are available for early-stage life science startups looking to improve their skill set in fundraising, business development, sales, and marketing.

Exhibiting at RESI – Connect with Top Life Science Startups

13 Apr

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

Redefining Early Stage Investments (the RESI conference series) is a unique gathering. Several hundred startup companies representing cutting-edge technologies from across the verticals of the life sciences attend RESI to meet the huge turnout of investors and to learn about the services that will help them develop and grow their companies.

Visibility and brand recognition with companies that will be raising funds and initiating R&D, pre-clinical, and clinical activities soon is key to add to the leads funnel. RESI gives service providers the chance to have an exhibit table right in the middle of all the activity, as well as a presence online, in our newsletter, and in the program guide.

In addition to meeting the startups, there is the opportunity to meet some of the hundreds of investors and licensing partners that have extensive portfolios of companies in need of crucial services.

For more information, reach out to the LSN Business Development Team!

Life Science Nation Business Development Team
International
East Coast (USA) & China
Midwest (USA)
& Canada
West Coast  (USA)
Cameron-Hurlburt
Greg Mannix
Vice President International Business Development
Book a Meeting
Email Me
Candice He
VP, Business Development & Global Investment Strategist
Book a Meeting
Email Me
Antoinette Lowre
Manager of Business Development
Book a Meeting
Email Me
Cameron Hurlburt
Manager of Business Development
Book a Meeting
Email Me

RESI-Boston-2023-June-1100px

Preparing for the Innovator’s Pitch Challenge (IPC) at RESI Boston

13 Apr

By Joey Wong, Investor Research Analyst, Hong Kong BD, LSN

LSN is once again featuring The Innovator’s Pitch Challenge (IPC) at the upcoming in-person RESI Boston on June 5. The IPC has been immensely popular among life science entrepreneurs and startup founders that attend RESI. The selected finalists will be grouped into sector-themed pitch sessions, and each company will have 4 minutes to present and 8 minutes for Q&A with an investor panel. The IPC offers a unique opportunity for founders and CEOs to engage directly with a panel of seasoned investors, who are specialized in the sectors that they judge for, so that the feedback and questions can be highly practical and constructive for the participants. The IPC is not only popular among startups, it is also valued by many active investors as an efficient way to engage with startups within their sector of interest. Whether you are a startup CEO or an investor, we welcome you to participate in IPC at our upcoming conference.

With two months left until RESI Boston, LSN is organizing an online workshop to help participants prepare for the IPC, ensuring that they can leverage the opportunity to the fullest extent. Please see below for the workshop schedule, and don’t forget to submit your application for the IPC before April 21, the final deadline. We highly recommend you to apply as early as possible, so you will have more time to prepare and maximize your experience. I look forward to seeing you at our webinar next week.

FREE_WEBINAR_IPC_Apr-18-Banner

Hot Investor Mandate: Asia-Based Evergreen Fund Invests in Early Clinical Stage Biotech and Medtech, Investing Up to $10M in Companies in Sizable Markets

13 Apr

An evergreen fund makes equity investments in early- to late-stage private businesses. Typical allocations range from USD 1.5 million to north of USD 10 million. The firm is most interested in companies addressing North Asia, USA, Europe, and LATAM markets.

The firm will invest in therapeutics, medical devices, diagnostics, and digital health products. In therapeutics, the firm is currently most interested in cell and gene therapy, nucleic acid drugs, and all novel drug delivery products. The firm prefers to invest from early clinical stage (Phase I) and beyond. In medical devices, the firm is opportunistic and is open to all types of technologies. In diagnostics, the firm is primarily interested in IVD and diagnostics tools. The firm prefers to invest in products that have entered clinical testing, and is open to investing in both 510k and PMA devices. Lastly, in digital health, the firm is open to all types of technologies including those that leverage AI. In terms of indications, the firm is most interested in chronic disease therapy / care, neuron disorders, and oncology.

The firm is looking for competent, experienced, and reliable management teams when considering investment. The fund typically requires a board seat in the companies it invests in.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.